Search results
... Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair...
Digital Journal· 2 days agoOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task forceTop line results imminent ...
Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and...
FOX 59 Indianapolis· 2 days agoLunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the American ...
The growing promise of cancer vaccines
Cosmos· 6 hours agoA cure for cancer — which is second only to cardiovascular diseases in its contribution to the global burden of disease — has long been a dream. While no magic bullet is yet in sight, three ...
Organ transplant reform draws Hill scrutiny
Politico· 2 days agoWhy it matters: The Food and Drug Administration is considering a drug application from Lykos Therapeutics for MDMA, also known as ecstasy, combined with talk therapy as a ...
... Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair...
San Mateo Daily Journal· 2 days agoOral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KSAN - KLST San Angelo· 23 hours agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...
StemCyte Renews Contract with the California State Umbilical Cord Blood Collection Program
CBS 47 Fresno· 3 days agoStemCyte, a leader in cord blood-based regenerative therapeutics in Southern California, is excited to announce the renewal of its partnership with the California State Umbilical ...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 3 days agoLarimar Up on Clinical Hold Removal: Larimar Therapeutics, Inc. LRMR announced that the FDA has...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
WFRV 5 Green Bay· 2 days ago...2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the results from the Phase I/IIa...
Harnessing RNAi: Alnylam’s Path From Lab Discovery to Life-Changing Treatments
SciTechDaily· 3 days agoAlnylam Pharmaceuticals, founded by MIT professors and former postdocs, has developed five FDA...
